Sat.Aug 10, 2024 - Fri.Aug 16, 2024

article thumbnail

Keeping Counterfeit Goods Out of the Supply Chain

Pharmaceutical Commerce

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, comments on other ways to limit ‘bad actors’ attempts to sneak counterfeit drugs into the supply chain, aside from the DSCSA.

Pharma 105
article thumbnail

With FDA approval of Livdelzi, Gilead launches an inflammatory drug for the first time

Fierce Pharma

With an FDA appro | The FDA has approved Gilead's primary biliary cholangitis treatment Livdelzi. The drug, which was acquired in a $4.3 billion buyout of CymaBay Therapeutics six months ago, is the first inflammatory treatment launched by Gilead.

FDA 344
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How Often Do LLMs Hallucinate When Producing Medical Summaries?

MedCity News

Researchers at the University of Massachusetts Amherst released a paper this week showing that large language models tend to hallucinate quite a bit when producing medical summaries. The post How Often Do LLMs Hallucinate When Producing Medical Summaries? appeared first on MedCity News.

Medical 142
article thumbnail

People need to know how to use AI now

pharmaphorum

With the implementation of advancing technologies in industry comes the parallel need for suitable upskilling of the workforce – but this doesn’t as yet always pan out, and in today’s pharmaphorum podcast COO of Enthought Mike Connell discusses the growing skills gap in R&D in life sciences and the 80/20 rule with web editor Nicole Raleigh, as well as the need for correct education of people and machines, both.

Education 119
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Study finds AI reduces underdiagnosis of Black patients with common heart failure

PharmaTimes

Heart failure with preserved ejection fraction makes up 50% of all UK heart failure cases

Patients 111
article thumbnail

To approve Amgen's lung cancer med Imdelltra, FDA saw past 'large number' of missing adverse events

Fierce Pharma

When the FDA approved Amgen’s Imdelltra in May, the T-cell engager was hailed as a breakthrough for the treatment of small cell lung cancer (SCLC) and as the first DLL3-targeting therapy of potenti | In granting an accelerated approval to Amgen's first-in-class DLL3 bispecific Imdelltra, the FDA had to work through a “large number” of missing adverse events from a pivotal trial.

FDA 328

More Trending

article thumbnail

AstraZeneca said to be wavering on £450m UK vaccine plant

pharmaphorum

AstraZeneca's plan to invest £450m in a vaccines plant in the UK has been thrown into doubt by a bid to slash state aid, reports FT

115
115
article thumbnail

How clinical trials can use AI responsibly and effectively

Pharmaceutical Technology

Strong measures must be in place to safeguard confidential patient data when deploying AI to optimise clinical trial translations.

Patients 107
article thumbnail

J&J and Roche are the strongest companies in the biopharma industry, says S&P Global

Fierce Pharma

Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers. | Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers.

Biopharma 325
article thumbnail

CMS Touts First Negotiated Drug Prices, But Greater Impact Expected in Future Rounds

MedCity News

The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come. The post CMS Touts First Negotiated Drug Prices, But Greater Impact Expected in Future Rounds appeared first on MedCity News.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Otsuka, Click's depression DTx launches in the US

pharmaphorum

Otsuka and Click Therapeutics' first-in-class prescription digital therapeutic for depression launches in US through mobile app stores

article thumbnail

Pharma Pulse 8/16/24: The Future of Launch Excellence is GenAI, Will Negotiated Drug Prices Actually Save Money? & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 105
article thumbnail

Ascendis scores hard-fought FDA nod for hormone replacement therapy Yorvipath

Fierce Pharma

Ascendis Pharma should be well prepared for the U.S. | After two delays, the FDA has finally signed off on Ascendis Pharma's hormone replacement therapy Yorvipath, also known as TransCon PTH, which is the first approved product for hypoparathyroidism in adults in the U.S.

FDA 321
article thumbnail

First Walgreens Store Files to Unionize with the Pharmacy Guild

MedCity News

Pharmacists and pharmacy technicians at a Walgreens store in Vancouver, Washington, have filed a petition to join the Pharmacy Guild. The workers argued that they are facing heavy workloads and inadequate staffing. The post First Walgreens Store Files to Unionize with the Pharmacy Guild appeared first on MedCity News.

126
126
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

MSD adds bispecific cancer antibody via $1.3bn Curon deal

pharmaphorum

MSD adds a bispecific antibody for blood cancers and autoimmune diseases to its pipeline via a $1.3bn licensing deal with Curon Biopharma.

Biopharma 112
article thumbnail

Pharma Pulse 8/13/24: How Should Biotechs Strategize for 2025, Pfizer Announces Top-Line Results of ABRYSVO for RSV & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 105
article thumbnail

Fiercest Women in Life Sciences 2024: Nominations open now

Fierce Pharma

It’s time once again to nominate the fiercest women you know in the life science industry for our annual list. | It’s time once again to nominate the fiercest women you know in the life science industry for our annual list.

316
316
article thumbnail

Adapting to a Patient-Centric Care Model with Tech-Enabled Urgent Care

MedCity News

As patient expectations evolve, the healthcare industry must evolve with them. This means the tools, processes, and technology involved in care delivery must adapt, too. The post Adapting to a Patient-Centric Care Model with Tech-Enabled Urgent Care appeared first on MedCity News.

Patients 126
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Incyte builds GvHD presence with Niktimvo approval

pharmaphorum

FDA clears Incyte's potential blockbuster Niktimvo as a treatment for chronic GvHD, making it a companion to the company's Jakafi for the disorder.

FDA 111
article thumbnail

Pharma Pulse 8/14/24: Brands Love Influencers.Until Politics Get Involved, Improving Pain Self-Management Among Rural, Older Cancer Patients & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 105
article thumbnail

Novo Nordisk plans new $220M raw ingredients plant in Denmark

Fierce Pharma

Even as supplies of Novo Nordisk’s immensely popular GLP-1 drugs Ozempic and Wegovy start to stabilize, the Danish drugmaker continues to announce manufacturing and capacity upgrades at a rapid cli | Novo Nordisk Pharmatech, a unit that specializes in producing drug ingredients, is spending 1.5 billion Danish kroner ($220 million) to build a plant in Køge, Denmark, that will make raw materials, the company said Friday.

article thumbnail

Fair Square Medicare Unveils Generative AI Platform for Medicare Organizations

MedCity News

Fair Square Medicare launched a new generative AI platform called Vox. It’s meant to be used by Medicare carriers and brokerages and has three main features: AI voice agents, generative AI-driven insights and AI-powered coaching. The post Fair Square Medicare Unveils Generative AI Platform for Medicare Organizations appeared first on MedCity News.

125
125
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

AI chatbots struggle to interpret patient descriptions

pharmaphorum

Large language models (LLMs) find it hard to identify genetic conditions based on patient-written descriptions, say NIH researchers.

Patients 111
article thumbnail

AstraZeneca wins approval for Imfinzi in NSCLC perioperative setting

Pharmaceutical Technology

The FDA approval of Imfinzi in this indication comes a month after the agency called for an overhaul of perioperative lung cancer trials.

FDA 105
article thumbnail

As mpox outbreak spreads across Africa, Siga's antiviral Tpoxx misses the bar in Congo study

Fierce Pharma

Just as a new strain of mpox spreads across Africa, results from a preliminary analysis of a study that began during the 2022 viral outbreak stands to provide more clarity on the clinical benefit o | Despite missing the trial's primary endpoint of time to lesion resolution, the study suggested that the treatment may be most beneficial for those treated early and those with severe disease.

311
311
article thumbnail

Study: LLMs Identify Mental Health Crises with Accuracy Comparable to Clinicians

MedCity News

OpenAI’s GPT-4 was able to identify suicidal ideation with similar accuracy to clinicians, but in a much shorter amount of time, a new study from Brightside Health found. The post Study: LLMs Identify Mental Health Crises with Accuracy Comparable to Clinicians appeared first on MedCity News.

126
126
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Remembering Paul Bannister, dear friend and finance manager

pharmaphorum

Our longtime Finance Director Paul Bannister was a part of the fabric of pharmaphorum almost from the beginning and an integral part of keeping the publication running. And, most importantly, he was the soul of the place and a friend to all.

article thumbnail

Complying with the DSCSA

Pharmaceutical Commerce

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, describes the outcome of the joint public meeting held by the Partnership for DSCSA Governance and the FDA.

article thumbnail

US court rules for AstraZeneca, erasing Pfizer's $107.5M jury award in patent infringement case

Fierce Pharma

Less than three months after a Delaware federal jury ordered AstraZeneca to pay $107.5 million to Pfizer in a patent infringement case, a Delaware judge has nullified the award and invalidated the | Less than three months after a Delaware federal jury ordered AstraZeneca to pay $107.5 million to Pfizer in a patent infringement case, a Delaware judge has nullified the award and invalidated the patents behind the original lawsuit.

304
304
article thumbnail

FDA Awards Accelerated Approval to Gilead Sciences Drug for Rare Liver Disease

MedCity News

Livdelzi is now FDA-approved for treating the rare liver disease primary biliary cholangitis. Gilead Sciences added the drug to its pipeline via the $4.3 billion acquisition of CymaBay Therapeutics earlier this year. The post FDA Awards Accelerated Approval to Gilead Sciences Drug for Rare Liver Disease appeared first on MedCity News.

FDA 125
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time